About Oramed Pharmaceuticals (NASDAQ:ORMP)
Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed's flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed's delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company's products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ORMP
CUSIPN/A
Phone011-972-2-566-0001
Debt
Debt-to-Equity RatioN/A
Current Ratio4.48%
Quick Ratio4.48%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.46 million
Price / Sales43.32
Cash FlowN/A
Price / CashN/A
Book Value$1.42 per share
Price / Book5.20
Profitability
EPS (Most Recent Fiscal Year)($0.79)
Net Income$-10,480,000.00
Net Margins-165.01%
Return on Equity-49.12%
Return on Assets-25.53%
Miscellaneous
Employees14
Outstanding Shares14,440,000
Oramed Pharmaceuticals (NASDAQ:ORMP) Frequently Asked Questions
What is Oramed Pharmaceuticals' stock symbol?
Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."
When is Oramed Pharmaceuticals' next earnings date?
What price target have analysts set for ORMP?
2 equities research analysts have issued 12-month target prices for Oramed Pharmaceuticals' stock. Their forecasts range from $20.00 to $25.00. On average, they anticipate Oramed Pharmaceuticals' stock price to reach $22.50 in the next year. View Analyst Ratings for Oramed Pharmaceuticals.
Who are some of Oramed Pharmaceuticals' key competitors?
Some companies that are related to Oramed Pharmaceuticals include Verastem (VSTM), Scpharmaceuticals (SCPH), Marinus Pharmaceuticals (MRNS), Ra Pharmaceuticals (RARX), POXEL (PXXLF), Xoma (XOMA), Summit Therapeutics (SMMT), Nabriva Therapeutics (NBRV), Zafgen (ZFGN), Teligent (TLGT), Protagonist Therapeutics (PTGX), Spero Therapeutics (SPRO), Kamada (KMDA), Immune Design (IMDZ), Spring Bank Pharmaceuticals (SBPH), Proteostasis Therapeutics (PTI), Avid Bioservices (CDMO) and Intec Pharma (NTEC).
Who are Oramed Pharmaceuticals' key executives?
Oramed Pharmaceuticals' management team includes the folowing people:
- Kevin L. Rakin, Chairman of the Board, Independent Director (Age 57)
- Nadav Kidron, President, Chief Executive Officer, Director (Age 43)
- Hilla Eisenberg, Chief Financial Officer, Treasurer, Secretary
- Joshua Hexter, Chief Operating Officer, Vice President - Business Development (Age 46)
- Miriam Kidron Ph.D., Chief Scientific Officer, Director (Age 76)
- Ronald Edward Law, Chief Strategy Officer (Age 64)
- Aviad Friedman, Independent Director (Age 45)
- Xiaopeng Li, Independent Director (Age 33)
- Leonard Sank, Independent Director (Age 52)
- David Slager, Independent Director (Age 44)
Has Oramed Pharmaceuticals been receiving favorable news coverage?
Press coverage about ORMP stock has trended somewhat positive recently, Accern reports. The research group identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Oramed Pharmaceuticals earned a news impact score of 0.23 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 44.94 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
How do I buy shares of Oramed Pharmaceuticals?
Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Oramed Pharmaceuticals' stock price today?
One share of ORMP stock can currently be purchased for approximately $7.38.
How big of a company is Oramed Pharmaceuticals?
Oramed Pharmaceuticals has a market capitalization of $106.59 million and generates $2.46 million in revenue each year. The biotechnology company earns $-10,480,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Oramed Pharmaceuticals employs 14 workers across the globe.
How can I contact Oramed Pharmaceuticals?
Oramed Pharmaceuticals' mailing address is HI-TECH PARK 2/4 GIVAT-RAM PO BOX 39098, JERUSALEM L3, 91390. The biotechnology company can be reached via phone at 011-972-2-566-0001 or via email at [email protected]
MarketBeat Community Rating for Oramed Pharmaceuticals (ORMP)
MarketBeat's community ratings are surveys of what our community members think about Oramed Pharmaceuticals and other stocks. Vote "Outperform" if you believe ORMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
Oramed Pharmaceuticals (NASDAQ:ORMP) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Oramed Pharmaceuticals (NASDAQ ORMP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 27.50%
Institutional Ownership Percentage: 2.62%
Oramed Pharmaceuticals (NASDAQ ORMP) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/2/2017 | Xiaopeng Li | Director | Buy | 89,636 | $8.50 | $761,906.00 | 206,350 |  |
| 4/19/2017 | Miriam Kidron | Insider | Sell | 52,814 | $6.33 | $334,312.62 | | |
| 5/12/2016 | Nadav Kidron | CEO | Buy | 1,000 | $6.95 | $6,950.00 | 957,448 | |
| 12/30/2015 | Miriam Kidron | CTO | Sell | 50,000 | $8.90 | $445,000.00 | 142,450 | |
| 12/9/2015 | Michael Berelowitz | Director | Sell | 700 | $9.44 | $6,608.00 | 22,896 | |
| 12/8/2015 | Michael Berelowitz | Director | Sell | 1,300 | $8.70 | $11,310.00 | 23,596 | |
| 3/19/2015 | Nadav Kidron | CEO | Buy | 2,600 | $3.88 | $10,088.00 | | |
| 9/11/2014 | Miriam Kidron | CTO | Sell | 31,699 | $8.41 | $266,588.59 | | |
| 9/10/2014 | Miriam Kidron | CTO | Sell | 23,000 | $8.40 | $193,200.00 | | |
| 9/4/2014 | Miriam Kidron | CTO | Sell | 8,301 | $9.41 | $78,112.41 | | |
| 6/6/2014 | Regals Capital Management Lp | Major Shareholder | Buy | 2,252 | $4.44 | $9,998.88 | | |
| 3/31/2014 | Michael Berelowitz | Director | Sell | 9,434 | $10.50 | $99,057.00 | | |
| 3/25/2014 | Regals Capital Management Lp | major shareholder | Buy | 75,000 | $10.62 | $796,500.00 | | |
| 2/6/2014 | Regals Capital Management Lp | major shareholder | Buy | 51,292 | $15.61 | $800,668.12 | | |
| 7/10/2013 | Regals Capital Management Lp | Major Shareholder | Buy | 6,630 | $7.40 | $49,062.00 | | |
(Data available from 1/1/2013 forward)
Oramed Pharmaceuticals (NASDAQ ORMP) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Oramed Pharmaceuticals (ORMP) Cut to Sell at ValuEngine
www.americanbankingnews.com - April 20 at 12:24 AM |
| FY2018 Earnings Estimate for Oramed Pharmaceuticals Inc. Issued By B. Riley (ORMP)
www.americanbankingnews.com - April 19 at 7:18 AM |
 | Form 4 ORAMED PHARMACEUTICALS For: Apr 08 Filed by: Hexter Joshua
www.streetinsider.com - April 11 at 8:31 AM |
| Oramed Pharmaceuticals (ORMP) Raised to Hold at ValuEngine
www.americanbankingnews.com - April 10 at 12:32 AM |
| Oramed Pharmaceuticals (ORMP) Given "Buy" Rating at B. Riley
www.americanbankingnews.com - March 28 at 12:58 PM |
 | Oramed to Present at HC Wainwright Annual Global Life Sciences Conference
www.prnewswire.com - March 27 at 5:13 PM |
 | Oramed to Present at H.C. Wainwright Annual Global Life Sciences Conference
finance.yahoo.com - March 27 at 8:28 AM |
| Oramed to Present at Oppenheimer's Annual Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - March 16 at 8:21 AM |
| Oramed to Present at Oppenheimer's Annual Healthcare Conference
finance.yahoo.com - March 15 at 6:11 PM |
| Oramed Adds Two New Members to its Scientific Advisory Board - PR Newswire (press release)
www.prnewswire.com - March 1 at 8:15 AM |
| Oramed to Present at the CODHy 6th World Congress on Diabetes, Obesity and Hypertension - PR Newswire (press release)
www.prnewswire.com - February 22 at 8:22 AM |
| Oramed Pharmaceuticals (ORMP) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - February 21 at 12:56 AM |
| Oramed to Present at the CODHy 6th World Congress on Diabetes, Obesity and Hypertension
finance.yahoo.com - February 20 at 5:46 PM |
| Head-To-Head Survey: SAGE Therapeutics (SAGE) versus Oramed Pharmaceuticals (ORMP)
www.americanbankingnews.com - February 10 at 12:44 PM |
| Oramed to Present at BIO CEO Investor Conference - PR Newswire (press release)
www.prnewswire.com - February 8 at 8:11 AM |
| Oramed to Present at BIO CEO Investor Conference
finance.yahoo.com - February 6 at 9:33 AM |
| FY2018 EPS Estimates for Oramed Pharmaceuticals, Inc. (ORMP) Lifted by Zacks Investment Research
www.americanbankingnews.com - February 1 at 12:32 PM |
 | Oramed Pharmaceuticals' CEO Issues Letter to Shareholders
www.bizjournals.com - January 19 at 11:48 AM |
| Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q1, 2018 By the Numbers : January 19, 2018
finance.yahoo.com - January 19 at 11:48 AM |
| Analysts Issue Forecasts for Oramed Pharmaceuticals, Inc.'s FY2018 Earnings (ORMP)
www.americanbankingnews.com - January 18 at 2:58 PM |
| Blog Exposure - AveXis Shares Details About Its Expanded Clinical Development Program for AVXS-101 for Treating Spinal Muscular Atrophy
finance.yahoo.com - January 18 at 11:16 AM |
| Oramed Pharmaceuticals (ORMP) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - January 1 at 2:20 PM |
| Oramed Pharmaceuticals (ORMP) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - December 23 at 4:14 PM |
| Oramed Pharmaceuticals, Inc. (ORMP) Expected to Post Q1 2018 Earnings of ($0.21) Per Share
www.americanbankingnews.com - December 13 at 10:26 AM |
| Oramed Pharmaceuticals' (ORMP) "Buy" Rating Reaffirmed at B. Riley
www.americanbankingnews.com - December 11 at 10:10 PM |
| B.Riley/FBR Resumes Oramed Pharma (ORMP) at Buy - StreetInsider.com
www.streetinsider.com - December 11 at 4:44 PM |
| ValuEngine Lowers Oramed Pharmaceuticals (ORMP) to Sell
www.americanbankingnews.com - December 5 at 10:12 PM |
 | Here's Why And How Oramed Pharmaceuticals Is Going After NASH
www.benzinga.com - November 28 at 4:31 PM |
| Oramed Pharmaceuticals' (ORMP) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - November 22 at 8:40 AM |
| Brokerages Expect Oramed Pharmaceuticals Inc. (ORMP) Will Post Quarterly Sales of $610,000.00
www.americanbankingnews.com - November 20 at 10:32 AM |
| Reviewing Oramed Pharmaceuticals (ORMP) and Its Peers
www.americanbankingnews.com - November 19 at 9:26 PM |
| Critical Comparison: Oramed Pharmaceuticals (ORMP) and Its Rivals
www.americanbankingnews.com - November 19 at 3:30 PM |
 | FDA Nod For AZN's Asthma Drug, Genmab Revises Outlook, NBY Disappoints - Nasdaq
www.nasdaq.com - November 15 at 7:10 AM |
| Oramed Pharma (ORMP) Granted Regulatory Approval to Conduct ... - StreetInsider.com
www.streetinsider.com - November 15 at 7:10 AM |
| Oramed Receives Regulatory Approval to Conduct Clinical Study for Treatment of NASH with its Oral Insulin Capsule
finance.yahoo.com - November 15 at 7:10 AM |
| Oramed Pharma (ORMP) Announces Composition of Matter Patent in Europe for Oral Proteins
www.streetinsider.com - November 2 at 7:22 AM |
| Oramed Pharma (ORMP) Announces Composition of Matter Patent in Europe for Oral Proteins - StreetInsider.com
www.streetinsider.com - November 1 at 7:18 AM |
| Oramed Granted Broad Composition of Matter Patent in Europe for Oral Proteins
finance.yahoo.com - November 1 at 7:18 AM |
| Oramed Pharmaceuticals Inc. (ORMP) Expected to Post Quarterly Sales of $610,000.00
www.americanbankingnews.com - October 30 at 4:02 AM |
| Oramed to Present at the Diabetes Technology Meeting
finance.yahoo.com - October 25 at 8:42 AM |
| Oramed Pharma (ORMP) Says Endocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored by its Scientists
www.streetinsider.com - October 18 at 1:50 AM |
| Oramed Pharma (ORMP) Says Endocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored ... - StreetInsider.com
www.streetinsider.com - October 17 at 3:45 PM |
| Endocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored by Oramed Scientists
finance.yahoo.com - October 17 at 3:45 PM |
| Contrasting Oramed Pharmaceuticals (ORMP) & OvaScience (OVAS)
www.americanbankingnews.com - October 7 at 6:28 PM |
| HC Wainwright Reiterates Buy Rating for Oramed Pharmaceuticals Inc. (ORMP)
www.americanbankingnews.com - October 5 at 3:38 PM |
| Oramed to Present at the Disruptive Growth Showcase Conference
finance.yahoo.com - October 2 at 9:19 PM |
| Oramed Now Has a Clear Path to Market With Oral Insulin
finance.yahoo.com - September 23 at 9:12 AM |
| Critical Analysis: Portola Pharmaceuticals (PTLA) versus Oramed Pharmaceuticals (ORMP)
www.americanbankingnews.com - September 12 at 2:26 AM |
| Oramed Pharma (ORMP) Says FDA Meeting Provides BLA Guidance on ORMD-0801
www.streetinsider.com - September 6 at 7:16 AM |
| Oramed Announces Successful Meeting with FDA for Oral Insulin
finance.yahoo.com - September 6 at 7:16 AM |
Oramed Pharmaceuticals (NASDAQ:ORMP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Oramed Pharmaceuticals (NASDAQ:ORMP) Income Statement, Balance Sheet and Cash Flow Statement
Oramed Pharmaceuticals (NASDAQ ORMP) Stock Chart for Friday, April, 20, 2018
Loading chart…
